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Abstract
Background—Malaria and iron deficiency (ID) in childhood are both associated with cognitive 
and behavioral dysfunction. The current standard of care for children with malaria and ID is 
concurrent antimalarial and iron therapy. Delaying iron therapy until inflammation subsides could 
increase iron absorption but also impair cognition.
Methods—In this study, Ugandan children 18 months to 5 years old with cerebral malaria (CM, 
n=79), severe malarial anemia (SMA, n=77) or community children (CC, n=83) were enrolled and 
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tested for ID. Children with ID were randomized to immediate vs. 28-day delayed iron therapy. 
Cognitive and neurobehavioral outcomes were assessed at baseline and 6 and 12 months (primary 
endpoint) after enrollment.
Results—All children with CM or SMA and 35 CC had ID (zinc protoporphyrin concentration 
≥80 μmol/mol heme). No significant differences were seen at 12-month follow-up in overall 
cognitive ability, attention, associative memory, or behavioral outcomes between immediate and 
delayed iron treatment (mean difference (standard error of mean) ranged from −0.2 (0.39) to 0.98 
(0.5), all P≥0.06).
Conclusion—Children with CM or SMA and ID who received immediate vs. delayed iron 
therapy had similar cognitive and neurobehavioral outcomes at 12-month follow-up.
INTRODUCTION
Malaria is a major contributor to the developmental gap faced by children in sub-Saharan 
Africa relative to other regions (1). Prior studies by our group demonstrated that two 
manifestations of severe malaria (SM), cerebral malaria (CM) and severe malarial anemia 
(SMA), both contribute to cognitive impairment in children (2,3). In addition, we recently 
demonstrated that children exhibit persistent neurobehavioral problems following SM, 
including more anxious and depressed symptoms in children with SMA, and more somatic 
complaints and aggressive behavior in children with either SMA or CM (4). Iron deficiency 
(ID), also common in much of sub-Saharan Africa, often coexists with Plasmodium 
falciparum malaria (5), and has well-established consequences on cognition and child 
behavior (6). Young children with ID exhibit a more fearful, withdrawn affect than their 
iron-sufficient peers (7), and chronic ID can lead to more internalizing symptoms and 
problems with attention that persist into adolescence even when iron is given on diagnosis of 
ID (7). Additionally, ID can affect multiple cognitive functions, including motor control, 
memory, and attention resulting, in poorer scholastic achievement, and problem-solving 
skills (8).
There is a complex interplay between iron status, malaria risk, and neurobehavioral 
development in malaria endemic areas. Studies show that iron therapy at the time of malaria 
treatment may lead to delayed parasite clearance and increased susceptibility to clinically 
significant P. falciparum malaria (9). Conversely, malaria can lead to anemia of 
inflammation. Levels of hepcidin and ferritin, an acute phase reactant implicated in iron 
metabolism, rise as a result of the inflammatory response to malaria, leading to sequestration 
of body iron and impaired iron absorption in the gut (10,11). Impaired iron absorption and 
sequestration of body iron can prevent utilization of iron for hematopoiesis and brain 
development (9). Studies of dietary ID (7,12–15) and studies of children with SM (2,4) have 
both shown impaired attention, internalizing, and externalizing behaviors, suggesting that 
dietary ID and malaria-related anemia of inflammation with reduced bioavailability of iron 
may act on the developing brain through similar and potentially additive pathways. Effective 
management of ID in SM could represent an important opportunity to limit the 
neurobehavioral toll of malaria. However, it is difficult to know the relative contributions of 
dietary ID and anemia of inflammation with reduced bioavailability of iron in a child 
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presenting with SM, as the profound inflammation that characterizes SM alters currently 
available iron biomarkers.
World Health Organization (WHO) guidelines recommend starting iron and antimalarial 
therapies concurrently when ID (defined as anemia or an abnormal value for any iron 
biomarker) and malaria occur concurrently (16). However, recent studies have demonstrated 
that the relative timing of antimalarial and iron therapies is important and that concurrent 
administration may not facilitate optimal iron intake into hemoglobin. A study of Gambian 
children recovering from malarial anemia demonstrated that iron incorporation into 
hemoglobin after iron supplementation remained significantly reduced two weeks after 
starting antimalarials, while iron incorporation in children recovering from iron deficiency 
anemia alone was excellent at baseline and two weeks later (11). In addition, a recent study 
of Ugandan children with malaria and anemia showed that iron incorporation into 
hemoglobin was twice as great when the start of iron therapy was delayed by four weeks vs. 
given concurrently (17). Together these findings suggest that delaying iron therapy until 
after parasite-induced inflammation and the resultant disruptions in iron metabolism are 
resolved may permit greater iron absorption and incorporation, and that four weeks may be 
the most appropriate delay. However, whether delaying iron supplementation constitutes a 
risk to the developing brain is unknown. We conducted a clinical trial in which children with 
SMA and CM who were iron-deficient (as defined by elevated zinc protoporphyrin), and 
iron-deficient community children, were randomized to start iron therapy either immediately 
or after 28 days and were assessed for malaria incidence, hemoglobin level, and cognitive 
and neurobehavioral outcomes over 12 months of follow-up. In this manuscript, we describe 
the results of immediate vs. 28-day delayed iron therapy on general cognitive ability and 
neurobehavioral outcomes at the 6- and 12-month follow-up visits.
METHODS
Participant Enrollment, Randomization, Iron Treatment and Follow-up
Children 18 months to 4.9 years of age with CM, SMA, or community children were 
enrolled at Mulago Hospital, Kampala, Uganda between June 2010 and September 2014. 
CM was defined as: 1) coma (Blantyre Coma Score ≤2); 2) Plasmodium falciparum on 
blood smear; and 3) no other known cause of coma. SMA was defined as presence of 
Plasmodium falciparum on blood smear in children with a hemoglobin (Hb) level ≤5 g/dL.
Community children (CC) 18 months to 4.9 years of age who were currently healthy with no 
symptoms of illness and no history of chronic illness were recruited from the extended 
family or household compound area of children with severe malaria. CC were enrolled to be 
in the same age range as children with CM or SMA, but were not matched to specific 
children with CM or SMA. Mean age and weight-for-age z-scores did not differ between 
children with CM or SMA and CC (18). Exclusion criteria for all children included 1) 
known chronic illness requiring medical care; 2) known developmental delay; or 3) history 
of coma, head trauma, hospitalization for malnutrition, or cerebral palsy.
Children with iron deficiency, defined as a zinc protoporphyrin (ZPP) level ≥ 80 μmol/mol 
heme, were randomized to receive a three-month course of daily oral ferrous sulfate 
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(2mg/kg/day) either concurrently with antimalarial treatment (immediate group) or 28 days 
after receiving antimalarial treatment (delayed group).
Complete details on participant enrollment, randomization, study iron treatment, and follow-
up are provided in our manuscript on the effect of immediate vs. delayed iron treatment in 
this study population on iron biomarkers, malaria incidence, and hemoglobin levels (18), and 
in Supplemental Methods S1 (online). The results showed that children with SMA in the 
delayed compared to immediate treatment group had lower mean soluble transferrin receptor 
(6.1 vs. 7.8 mg/L, p=0.03) and zinc protoporphyrin (83 vs. 106 μmol/mol heme, p=0.02) 
after 12 months and showed a non-significant trend toward fewer episodes of severe malaria 
(incidence rate ratio [95% confidence interval), 0.39 [0.14, 1.12]) (18).
Cognitive Testing
Children were assessed for general cognitive ability, sustained attention, and associative 
memory a week after discharge (CM or SMA) or at enrollment (CC). These assessments 
were repeated at 6 and 12 months after enrollment. The assessments were conducted from 
the cognitive testing rooms on the pediatric ward at Mulago National Referral Hospital. 
Assessments were carried out by neuropsychological testers with undergraduate degrees in 
Psychology. They were blinded to the participant’s study group and treatment arms and not 
involved in the randomization or clinical procedures. The Mullen Scales of Early Learning 
(MSEL) (19), which assesses motor, visual, and language ability, were used to measure 
general cognitive ability. Scores from fine motor, visual reception, receptive language, and 
expressive language scales were summed to give the early learning composite score, a 
measure of general cognitive ability. Ability to sustain attention was assessed using the Early 
Childhood Vigilance Test (ECVT) (20), where a child is asked to focus his or her gaze on 
cartoons screened on a computer for approximately 7 minutes; the measure of sustained 
attention is the percentage of time the child spends gazing at the screen. Associative memory 
was assessed using the Color Object Association Test (COAT) (21), in which children are 
required to associate toys with specific color-coded boxes and scored on the total number of 
toys placed in the correct boxes. The MSEL, COAT and ECVT have been successfully used 
to assess cognition, memory and attention in multiple studies of children with HIV or 
malaria in Uganda (2,22). The tests used designed to assess children in the study’s age range 
and have been used and validated in a number of studies and cross-cultural settings in 
Uganda and sub-Saharan Africa (4,23–26).
Socio-Emotional Behavioral Testing
Baseline neurobehavioral testing was performed one-week post-discharge for children with 
CM or SMA and at enrollment for CC. Assessments were repeated 6 and 12 months after 
enrollment. Primary outcomes were age-adjusted z-scores at 12-month follow-up for: 1) 
internalizing, externalizing, and total behavioral problems, assessed with the parent-report 
preschool Child Behavioral Checklist (CBCL) (27); 2) global executive function, evaluated 
using the parent-report Behavior Rating Inventory of Executive Functioning, Preschool 
edition (BRIEF-P) (28); and age-adjusted scores for 3) observer-rated affect and behaviors, 
coded using the Behavior Rating Scales (BRS), developed by Lozoff and colleagues to 
capture behavioral domains associated with ID (7), adapted by author MK for use with older 
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children (29), and assessed from videotaped cognitive testing sessions by an experienced 
BRS coder at the University of Minnesota. The CBCL is a parent report tool focused on 
indicators of externalizing and internalizing behavior. The BRIEF is a parent report tool 
focused on indicators of emotional regulation and executive functioning. Literate parents 
completed printed versions of the two tools themselves; illiterate parents were read all items 
in each tool verbatim in a language of their choosing (English or Luganda), and their verbal 
responses were recorded by a trained tester.
The CBCL and BRIEF have previously been adapted for use in Uganda (25), while the BRS 
was adapted for this study by author MK (details in Supplemental Methods S2 [online]) and 
coded by an experienced coder (intra-class correlation coefficient >0.8). For the CBCL, 
children were scored on the syndrome scales, which are: emotionally reactive, anxious/
depressed, somatic complaints, withdrawn, attention problems, aggressive behavior, and 
sleep problems. These were summarized into internalizing problems (emotionally reactive, 
anxious/depressed, somatic complaints, withdrawn), externalizing problems (attention 
problems, aggressive behavior) and total problems, which included both internalizing and 
externalizing problems as well as 2 more scales, sleep problems and other problems (4,23).
Secondary outcomes included 12-month follow-up sub-scale scores of the BRIEF-P and 
CBCL; and baseline and 6-month follow-up global executive function, internalizing 
behavior, externalizing behavior, total behavioral problems, and observer-rated behavior 
scores. For CBCL and BRIEF scores and subscales, higher scores indicate more problematic 
behavior or diminished function. For the BRS, higher raw scores on Fearful/Wary Affect, 
Negative Affect and Hyperactivity/Over-activity, and lower raw scores on Positive Affect, 
Adaptation to Change, and Exploration and Activity Level, indicated more problematic 
behavior.
Statistical Analysis
Age-adjusted z-scores for general cognitive and neurobehavioral outcomes were computed 
using the scores of community children (CC) age 18 months – 4.9 years enrolled in a 
parallel prospective longitudinal cohort study of children with CM, SMA or CC that did not 
include iron treatment (2). Scores from asymptomatic community children were used to 
generate age-adjusted z-scores because this provided population-specific normative values 
for cognitive and behavioral outcomes, as opposed to using the US-based norms given with 
most tests, which would be inappropriate for this population.
For each outcome, the z score was computed as (actual score – mean score for child’s age)/
standard deviation (SD), where the mean score for age and SD were computed by fitting a 
mixed linear model to data from all available visits for CC in the parallel study (2) (allowing 
correlated errors for a child’s multiple visits); z scores have a mean of 0 and SD 1 in the 
reference population (CC) over all time points.
Five of seven BRS outcomes were heavily skewed and could not be converted to a z-score. 
These skewed scales were converted to categorical outcomes that best matched the scale 
distribution. For Fearful/Wary Affect, Negative Affect, Positive Affect, Overall 
Hyperactivity/Over-activity, any expression was termed “present” and no expression was 
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termed “absent.” For Overall Adaptation to Change/Cooperation, scores equal to or above 
the median were termed “present,” and a score below the median “absent.”
To estimate the mean age-adjusted z-score differences (I – D) at baseline, 6 and 12 months, 
linear regression models were fitted separately for each study group (CM, SMA, CC). 
Categorical BRS outcomes, adjusted for age and sex, were compared by logistic regression. 
The three primary outcomes at 12 months were pre-specified and no adjustment for multiple 
testing was made to P values. For outcomes at baseline and 6 months, we adjusted for 
multiple testing using Holm’s sequential Bonferroni procedure (30). Hemoglobin at baseline 
and malaria incidence over the 12-month follow-up period did not differ between I and D 
treatment arms and so were not adjusted for in analysis. Data was analyzed using STATA 
version 12.1 (Stata Corp, Texas). Sample sizes of 50 CC, 80 CM and 100 SMA, equally 
allocated between delayed and immediate iron treatment groups were estimated a priori to 
give 89% power (α = 0.05) to detect a 1 SD difference in z scores between the CM group 
with the immediate treatment strategy and other malaria-iron treatment groups
RESULTS
Study cohort characteristics
The numbers of children tested for general cognitive and neurobehavioral outcomes at each 
time point are shown in Supplemental Figure S1 (online). All tests of cognition and behavior 
used were designed for children <5 years, so testing numbers decreased as some children 
became >5 years old.
Baseline demographic, clinical and laboratory findings are summarized in the accompanying 
manuscript on iron biomarkers and malaria incidence and in Supplemental Table S1a for the 
children who received iron treatment (online). All variables, including home environment 
and socioeconomic status, were similar in each disease group in the I vs. D treatment arms.
Cognitive outcomes at 12-month follow-up
For the primary cognitive outcome endpoint (cognitive outcomes at 12-month follow-up), 
there were no statistically significant differences between children in the immediate 
compared to delayed treatment arm in any study group (CM, SMA or CC) for any cognitive 
outcome (general cognitive ability, sustained attention, associative memory, Table 1 and 
Figure 1).
Effect sizes for differences in immediate and delayed treatment arms were small (<0.5) for 
all cognitive outcomes for children with severe malaria (CM or SMA, Table 1). Effect size 
was larger for associative memory for CC, with a mean difference (standard error of mean 
(SE) of 0.98 (0.50), p=0.06, favoring immediate therapy. Overall, scores for cognitive ability 
were lower in children with CM or SMA were lower than CC, but the study was not 
designed or powered to assess statistical differences between these study groups.
Cognitive outcomes at baseline and 6-month follow-up
No significant differences between immediate and delayed iron treatment arms were seen for 
any cognitive z-score at baseline or 6 month follow-up testing for children with SMA, but 
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modestly higher z-scores in general cognitive ability were seen at baseline in CC in the 
immediate treatment arm (mean difference (SE), +0.77 (0.33), p=0.03) and at 6-month 
follow-up in children with CM in the immediate (+0.70 (0.28), p=0.01 (Table 2 and Figure 
1).
Socioemotional behavior at 12-month follow-up
For the primary behavioral endpoint (neurobehavioral outcomes at 12-month follow-up), no 
significant differences in internalizing, externalizing, or total problem behaviors on the 
CBCL were seen for I vs. D iron therapy for any study group (Table 3, S3), nor were any 
significant differences seen in the CBCL sub-scales (Table 5, S5). Similarly, no significant 
differences were seen in BRIEF global executive composite (Table 3, S3) or subscale z-
scores (Table 5, S5). Analyzing observed behavior, no differences were seen in the Behavior 
Rating Scales outcomes between the I vs. D iron treatment arms for children in any study 
group (Tables 4a and 4b).
Socioemotional behavior at baseline and 6-month follow-up
No significant differences were seen in socioemotional, executive function or observed 
behavior scores between I and D treatment groups in any study group at baseline or at 6-
month follow-up (Supplemental Tables S2 a–d [online]).
DISCUSSION
In this randomized clinical trial of immediate vs. 28-day delayed iron therapy for children 
with severe malaria and iron deficiency, general cognitive and neurobehavioral outcomes 
were similar at 12 months in children who started iron 28 days after antimalarial treatment 
as compared to those who started iron at the time of antimalarial treatment. The study was 
powered to detect a fairly large difference in cognitive or behavioral z-scores (one standard 
deviation [SD]), so it is possible that smaller differences were present and not detected. 
Future studies with larger sample sizes are needed to clarify the current study findings, and 
the studies may also need longer follow-up time, as the effects of iron supplementation may 
take additional time to evaluate. Interestingly, the only large effect sizes seen for cognition 
(>0.5 z-score) were in the community children, with a mean difference of 0.98 (standard 
error 0.5) for associative memory, favoring the immediate treatment arm (p=0.06). This 
finding suggests that in the absence of inflammation, children with ID as defined by ZPP 
may do better with immediate treatment.
Iron plays a role in the regulation of dopaminergic activity where dopamine, a key 
neurotransmitter in the extrapyramidal system of the brain, acts as a powerful regulator of 
many aspects of cognitive brain function (31), and modulates externally focused and 
internally directed attention, concentration, motivational processes and working memory 
(32). Numerous studies have demonstrated that iron deficiency is associated with an 
impairment in multiple cognitive domains, including general cognitive ability, executive 
function, recognition memory, inhibitory control, and sustained attention (7,15,33,34) and 
impairment in multiple areas of behavior (7,12,13,15).
Ssemata et al. Page 7
Pediatr Res. Author manuscript; available in PMC 2020 November 13.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
Detection of dietary ID during an episode of severe malaria is problematic, as virtually all 
measures of ID are affected by inflammation and/or hemolysis that occurs in severe malaria. 
Studies of dietary ID and development have used composite measures, which often include 
one or more of: ZPP, mean corpuscular volume (MCV), transferrin saturation, and levels of 
serum ferritin, hepcidin, and soluble transferrin receptor (34). ZPP, ferritin and hepcidin 
(35,36) levels are strongly affected by inflammation; transferrin saturation depends on serum 
iron levels, which are an unreliable marker of iron deficiency; MCV lacks sensitivity; and 
serum transferrin receptor levels are altered by the hemolysis seen in malaria (5,37,38). 
Thus, there is no ideal marker for dietary ID during acute severe malaria. We chose ZPP 
because it is a point-of-care test for ID and because children in the Pemba study (39) who 
had an elevated ZPP level and received iron therapy experienced fewer hospitalizations and 
deaths than children with elevated ZPP who did not receive iron. It is possible, however, that 
a biomarker that predicts subsequent mortality and morbidity risk may not be the same as 
one that predicts improved neurobehavioral outcomes. The elevated blood concentrations of 
ZPP, CRP and ferritin at baseline among children with severe malaria suggest sequestered 
iron and therefore reduced iron bioavailability, with iron not going to the sites most needed 
(blood cells, brain).
The resolution of inflammation and consequent release of sequestered iron may be sufficient 
to correct disruptions in iron absorption and utilization alone, without additional iron 
therapy. Without a no-iron treatment arm in children with severe malaria, this study could 
not answer the question of whether iron therapy was required for all of these children.
However, starting supplementation earlier in life and/or more prolonged follow-up may be 
required to determine if delayed iron treatment has a long-term effect on cognition. Previous 
studies by our group showed that delayed iron resulted in improved iron incorporation and 
lower hepcidin after 28 days (17,40). In the present study, we report elsewhere that children 
who received delayed iron treatment also had improved iron status at 12 month follow-up 
(18). These findings suggest that assessment of cognitive outcomes at longer follow-up (e.g., 
2 years) in this population may be important to fully address the question of whether delayed 
iron treatment determine if delayed iron treatment has a long-term effect on cognition in 
children with severe malaria and reduced iron bioavailability.
In addition, prior studies of iron therapy to improve neurobehavioral outcomes in children 
under 2 years with dietary ID, including one that followed subjects into adolescence, have 
not demonstrated a clear long-term neurobehavioral benefit to iron treatment once dietary ID 
is established. Conversely, the dopamine signaling effects of acute, dietary ID in preschool- 
and school-aged children have been shown to resolve in less than 8 weeks with iron therapy 
(13,15). Thus, the benefits of iron treatment in children ≥2 years of age with previous dietary 
ID requires further study. In addition, possible benefits of acute vs. delayed iron in children 
with reduced iron bioavailability who are <2 years also requires further study, since children 
<2 years may be at the highest risk of brain injury from iron deficiency, but only a small 
proportion of the children enrolled in the present study were <2 years of age.
Assessment of behavior is a complex, culturally dependent process. The CBCL and BRIEF 
have been used and validated in numerous countries and cultural settings (41,42), including 
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in Uganda (4,25). The Behavior Rating Scales (BRS) have been used in other countries and 
were adapted and piloted in Uganda prior to study implementation (7,41–43). Luganda-
proficient neuropsychology testers were available on site for questions on verbal responses. 
This access was important because although some behaviors, like fear and hyperactivity, can 
be assessed based on facial cues and body language with relative accuracy, others, like 
positive affect and cooperation, may lose nuance without fluency in the language in which 
the observed interaction is conducted.
Even without general cognitive or neurobehavioral benefits, delayed iron therapy may have 
clinical and physiologic benefits for children with malaria. In our assessment of iron 
biomarkers in this same study, we found a significantly lower prevalence of ID based on 
ZPP in children with SMA in the delayed iron group at 12-month follow-up (18). 
Additionally, a recent study comparing immediate and delayed iron for ID in uncomplicated 
malaria suggested that delayed iron was associated with a lower incidence of sick child visits 
as compared to immediate iron (44). Given the potential benefit to iron status and the 
reduced infection risk associated with delayed iron therapy, the lack of harmful effects on 
general cognitive and neurobehavioral outcomes reported in this analysis suggests that 
delayed iron therapy may be a safe and potentially superior alternative to the current 
standard of care for children with ID and SM.
In conclusion, compared to immediate iron therapy, 28-day delayed iron therapy did not 
alter general cognitive or neurobehavioral outcomes at 12-month follow-up in children with 
SM and ZPP-level defined ID. Additional studies are required to answer a number of 
questions raised by the present study, including how to define ID in SM, what biomarker(s) 
best predicts neurobehavioral outcomes in the context of ID and SM, the optimal age at 
which to provide iron therapy for ID, and whether inflammation-related sequestration of iron 
has the same effects on neurobehavioral outcomes as dietary ID. In addition, studies that 
overcome some of the limitations of our study, including the small sample size for children 
<2 years of age, and the ability to detect only relatively large differences in cognitive and 
behavioral outcomes (one standard deviation or greater), are also required before definitive 
recommendations can be made on the timing of iron treatment in severe malaria. Iron status 
and the timing of iron therapy in malaria remain important areas of study because of the 
potential risks of iron therapy in dietary iron-replete children in malaria endemic areas and 
because the populations at risk for malaria and iron undernutrition overlap so extensively.
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Impact
• The optimal time to provide iron therapy in children with severe malaria is not 
known. The present study shows that delay of iron treatment to 28 days after 
the malaria episode, does not lead to worse cognitive or behavioral outcomes 
at 12-month follow-up.
• The study contributes new data to the ongoing discussion of how best to treat 
iron deficiency in children with severe malaria.
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Figure 1. 
Age-adjusted neuropsychological scores in children with cerebral malaria (CM), severe 
malaria anemia (SMA) and community children (CC) at baseline (0), 6 and 12 months for 
general cognitive ability, sustained attention, and associative memory. Scores are shown as 
unadjusted means with 95% confidence intervals.
Ssemata et al. Page 14
Pediatr Res. Author manuscript; available in PMC 2020 November 13.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
Ssemata et al. Page 15
Ta
b
le
 1
.
C
og
ni
tiv
e 
ab
ili
ty
, a
tte
nt
io
n,
 a
nd
 a
ss
oc
ia
tiv
e 
m
em
or
y 
in
 c
hi
ld
re
n 
w
ith
 c
er
eb
ra
l m
al
ar
ia
, s
ev
er
e 
m
al
ar
ia
l a
ne
m
ia
, o
r 
co
m
m
un
ity
 c
hi
ld
re
n,
 b
y 
tr
ea
tm
en
t g
ro
up
 
at
 1
2-
m
on
th
 f
ol
lo
w
-u
pa
Sc
or
e 
an
d 
ou
tc
om
e
C
er
eb
ra
l m
al
ar
ia
Se
ve
re
 m
al
ar
ia
l a
ne
m
ia
C
om
m
un
it
y 
co
nt
ro
ls
Z
 s
co
re
 a
t 
12
 
m
o,
 m
ea
n±
SE
Im
m
ed
ia
te
 
(N
=3
0)
D
el
ay
ed
 
(N
=2
3)
M
ea
n 
di
ff
er
en
ce
 
(S
E
),
 I
 v
s.
 D
P
Im
m
ed
ia
te
 
(N
=2
9)
D
el
ay
ed
 
(N
=3
2)
M
ea
n 
di
ff
er
en
ce
 
(S
E
),
 I
 v
s.
 D
P
Im
m
ed
ia
te
 
(N
=1
6)
D
el
ay
ed
 
(N
=1
5)
M
ea
n 
di
ff
er
en
ce
 
(S
E
),
 I
 v
s.
 D
P
 
C
og
ni
tiv
e 
ab
ili
ty
−
0.
46
±
 0
.2
2
−
0.
49
 ±
 0
.2
5
0.
03
 (
0.
33
)
0.
92
−
0.
82
 ±
 0
.2
8
−
0.
62
 ±
 0
.2
8
−
0.
20
 (
0.
39
)
0.
61
0.
29
 ±
 0
.2
2
−
0.
34
 ±
 0
.2
3
0.
63
 (
0.
33
)
0.
07
 
A
tte
nt
io
n
−
0.
38
±
 0
.1
6
−
0.
81
 ±
 0
.1
8
0.
43
 (
0.
24
)
0.
08
−
0.
04
 ±
 0
.2
3
−
0.
12
 ±
 0
.2
2
0.
08
 (
0.
31
)
0.
81
−
0.
42
 ±
 0
.3
2
−
0.
83
 ±
 0
.3
3
0.
41
 (
0.
47
)
0.
39
 
A
ss
oc
ia
tiv
e 
m
em
or
y
−
0.
22
 ±
 0
.2
0
−
0.
39
 ±
 0
.2
3
0.
16
 (
0.
31
)
0.
60
−
0.
18
 ±
 0
.1
4
−
0.
14
 ±
 0
.1
4
−
0.
04
 (
0.
19
)
0.
85
0.
64
 ±
 0
.3
4
−
0.
34
 ±
 0
.3
5
0.
98
 (
0.
50
)
0.
06
a.
Z
-s
co
re
s 
w
er
e 
ag
e-
ad
ju
st
ed
 u
si
ng
 c
om
m
un
ity
 c
on
tr
ol
 c
hi
ld
re
n 
as
 th
e 
re
fe
re
nc
e 
po
pu
la
tio
n.
 L
in
ea
r 
re
gr
es
si
on
 m
od
el
s 
w
er
e 
us
ed
 to
 c
om
pa
re
 m
ea
n 
ne
ur
oc
og
ni
tiv
e 
ou
tc
om
es
 b
et
w
ee
n 
th
e 
im
m
ed
ia
te
 a
nd
 
de
la
ye
d 
tr
ea
tm
en
t g
ro
up
s 
w
ith
in
 e
ac
h 
st
ud
y 
gr
ou
p 
(C
M
, S
M
A
, C
C
) 
an
d 
al
l a
na
ly
se
s 
w
er
e 
ad
ju
st
ed
 f
or
 s
ex
.
A
bb
re
vi
at
io
ns
: m
o.
, m
on
th
s;
 P
, P
-V
al
ue
; S
E
, s
ta
nd
ar
d 
er
ro
r.
Pediatr Res. Author manuscript; available in PMC 2020 November 13.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
Ssemata et al. Page 16
Ta
b
le
 2
.
C
og
ni
tiv
e 
ab
ili
ty
, a
tte
nt
io
n 
an
d 
as
so
ci
at
iv
e 
m
em
or
y 
in
 c
hi
ld
re
n 
w
ith
 c
er
eb
ra
l m
al
ar
ia
, s
ev
er
e 
m
al
ar
ia
l a
ne
m
ia
, o
r 
co
m
m
un
ity
 c
hi
ld
re
n 
by
 tr
ea
tm
en
t g
ro
up
 
at
 b
as
el
in
e 
an
d 
6-
m
on
th
 f
ol
lo
w
-u
pa
Sc
or
e 
an
d 
ou
tc
om
e
C
er
eb
ra
l m
al
ar
ia
Se
ve
re
 m
al
ar
ia
l a
ne
m
ia
C
om
m
un
it
y 
co
nt
ro
ls
Im
m
ed
ia
te
 
(N
=3
8)
D
el
ay
ed
 
(N
=3
2)
M
ea
n 
di
ff
er
en
ce
 
(S
E
),
 I
 v
s.
 D
P
Im
m
ed
ia
te
 
(N
=3
8)
D
el
ay
ed
 
(N
=3
6)
M
ea
n 
di
ff
er
en
ce
 
(S
E
),
 I
 v
s.
 D
P
Im
m
ed
ia
te
 
(N
=1
9)
D
el
ay
ed
 
(N
=1
6)
M
ea
n 
di
ff
er
en
ce
 
(S
E
),
 I
 v
s.
 D
P
Z
 s
co
re
 a
t 
ba
se
lin
e,
 m
ea
n
±S
E
 
C
og
ni
tiv
e 
ab
ili
ty
−
0.
85
 ±
 0
.2
6
−
1.
01
 ±
 0
.2
8
0.
16
 (
0.
38
)
0.
67
−
1.
14
 ±
 0
.2
1
−
0.
86
 ±
 0
.2
1
−
0.
28
 (
0.
30
)
0.
35
0.
06
 ±
 0
.2
2
−
0.
71
 ±
 0
.2
4
0.
77
 (
0.
33
)
0.
03
 
A
tte
nt
io
n
−
0.
02
 ±
 0
.1
9
−
0.
48
 ±
 0
.2
2
0.
46
 (
0.
29
)
0.
12
0.
18
 ±
 0
.1
7
0.
47
 ±
 0
.1
8
−
0.
29
 (
0.
25
)
0.
24
0.
18
 ±
 0
.2
2
−
0.
42
 ±
 0
.2
4
0.
60
 (
0.
33
)
0.
08
 
A
ss
oc
ia
tiv
e 
m
em
or
y
−
0.
27
 ±
 0
.1
1
−
0.
29
 ±
 0
.1
2
0.
02
 (
0.
16
)
0.
93
−
0.
20
 ±
 0
.1
2
−
0.
03
 ±
 0
.1
3
−
0.
17
 (
0.
17
)
0.
34
−
0.
12
 ±
 0
.1
3
−
0.
25
 ±
 0
.1
4
0.
13
 (
0.
19
)
0.
49
Z
 s
co
re
 a
t 
6 
m
o,
 
m
ea
n±
SE
N
=
34
N
=
27
N
=
33
N
=
34
N
=
18
N
=
15
 
C
og
ni
tiv
e 
ab
ili
ty
−
0.
66
 ±
 0
.2
6
−
1.
14
 ±
 0
.2
9
0.
49
 (
0.
39
)
0.
22
−
0.
93
 ±
 0
.2
4
−
0.
57
 ±
 0
.2
4
−
0.
36
 (
0.
34
)
0.
29
0.
10
 ±
 0
.1
8
−
0.
41
 ±
 0
.2
0
0.
52
 (
0.
28
)
0.
07
 
A
tte
nt
io
n
−
0.
14
 ±
 0
.1
8
−
0.
84
 ±
 0
.2
1
0.
70
 (
0.
28
)
0.
01
0.
15
 ±
 0
.1
7
−
0.
09
 ±
 0
.1
7
0.
24
 (
0.
24
)
0.
31
−
0.
61
 ±
 0
.2
5
−
0.
46
 ±
 0
.2
8
−
0.
16
 (
0.
38
)
0.
68
 
A
ss
oc
ia
tiv
e 
m
em
or
y
−
0.
44
 ±
 0
.1
0
−
0.
43
 ±
 0
.1
2
0.
00
 (
0.
16
)
0.
98
−
0.
18
 ±
 0
.1
0
−
0.
05
 ±
 0
.0
9
−
0.
13
 (
0.
14
)
0.
34
0.
02
 ±
 0
.1
5
−
0.
32
 ±
 0
.1
6
0.
34
 (
0.
22
)
0.
14
a.
A
ge
-a
dj
us
te
d 
z-
sc
or
es
 w
er
e 
co
m
pu
te
d 
us
in
g 
co
m
m
un
ity
 c
on
tr
ol
 c
hi
ld
re
n 
as
 th
e 
re
fe
re
nc
e 
po
pu
la
tio
n.
 L
in
ea
r 
re
gr
es
si
on
 m
od
el
s 
w
er
e 
us
ed
 to
 c
om
pa
re
 m
ea
n 
ne
ur
oc
og
ni
tiv
e 
ou
tc
om
es
 b
et
w
ee
n 
th
e 
im
m
ed
ia
te
 a
nd
 d
el
ay
ed
 tr
ea
tm
en
t g
ro
up
s 
w
ith
in
 e
ac
h 
st
ud
y 
gr
ou
p 
(C
M
, S
M
A
, C
C
) 
an
d 
al
l a
na
ly
se
s 
w
er
e 
ad
ju
st
ed
 f
or
 s
ex
. F
or
 b
as
el
in
e 
an
d 
6-
m
on
th
 c
om
pa
ri
so
ns
, w
hi
ch
 w
er
e 
se
co
nd
ar
y 
co
m
pa
ri
so
ns
 w
ith
 
m
ul
tip
le
 o
ut
co
m
es
, n
on
e 
w
as
 s
ig
ni
fi
ca
nt
 f
ol
lo
w
in
g 
H
ol
m
’s
 s
eq
ue
nt
ia
l B
on
fe
rr
on
i c
or
re
ct
io
n 
fo
r 
m
ul
tip
le
 te
st
in
g.
A
bb
re
vi
at
io
ns
: m
o.
, m
on
th
s;
 P
, P
-V
al
ue
; S
E
, s
ta
nd
ar
d 
er
ro
r.
Pediatr Res. Author manuscript; available in PMC 2020 November 13.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
Ssemata et al. Page 17
Ta
b
le
 3
.
So
ci
oe
m
ot
io
na
l a
nd
 E
xe
cu
tiv
e 
Fu
nc
tio
n 
O
ut
co
m
es
 a
t 1
2-
m
on
th
 F
ol
lo
w
-u
pa
C
er
eb
ra
l M
al
ar
ia
Se
ve
re
 M
al
ar
ia
l A
ne
m
ia
C
om
m
un
it
y 
C
on
tr
ol
s
M
ea
n 
di
ff
er
en
ce
 (
95
 %
 C
I)
, I
 (
n=
30
) 
vs
. D
 
(n
=2
4)
P
M
ea
n 
di
ff
er
en
ce
 (
95
 %
 C
I)
, I
 (
n=
28
) 
vs
. D
 (
n=
32
)
P
M
ea
n 
di
ff
er
en
ce
 (
95
 %
 C
I)
, I
 (
n=
16
) 
vs
. D
 (
n=
15
)
P
C
hi
ld
 B
eh
av
io
ra
l C
he
ck
lis
t 
(C
B
C
L
)
In
te
rn
al
iz
in
g 
z-
sc
or
e
−
0.
08
 (
−
0.
55
, 0
.3
8)
0.
73
0.
12
 (
−
0.
58
, 0
.8
1)
0.
74
−
0.
26
 (
−
1.
12
, 0
.6
0)
0.
54
E
xt
er
na
liz
in
g 
z-
sc
or
e
0.
49
 (
−
0.
08
, 1
.0
6)
0.
09
−
0.
10
 (
−
0.
70
, 0
.5
0)
0.
74
−
0.
40
 (
−
1.
02
, 0
.2
2)
0.
20
To
ta
l P
ro
bl
em
s 
z-
sc
or
e
0.
22
 (
−
0.
33
, 0
.7
8)
0.
43
−
0.
04
 (
−
0.
71
, 0
.6
2)
0.
89
−
0.
42
 (
−
1.
18
, 0
.3
4)
0.
27
B
eh
av
io
r 
R
at
in
g 
In
ve
nt
or
y 
of
 E
xe
cu
ti
ve
 F
un
ct
io
n 
(B
R
IE
F
)
G
lo
ba
l E
xe
cu
tiv
e 
C
om
po
si
te
 z
-s
co
re
0.
24
 (
−
0.
47
, 0
.9
5)
0.
50
−
0.
00
 (
−
0.
61
, 0
.6
0)
1.
00
−
0.
37
 (
−
1.
12
, 0
.3
8)
0.
32
a.
L
in
ea
r 
re
gr
es
si
on
 m
od
el
s 
w
er
e 
pe
rf
or
m
ed
 s
ep
ar
at
el
y 
by
 s
tu
dy
 g
ro
up
 a
nd
 a
ll 
an
al
ys
es
 w
er
e 
ad
ju
st
ed
 f
or
 a
ge
 a
nd
 s
ex
.
A
bb
re
vi
at
io
ns
: I
, I
m
m
ed
ia
te
 ir
on
; D
, D
el
ay
ed
 ir
on
; P
, P
-v
al
ue
; C
I,
 c
on
fi
de
nc
e 
in
te
rv
al
.
Pediatr Res. Author manuscript; available in PMC 2020 November 13.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
Ssemata et al. Page 18
Ta
b
le
 4
a.
O
bs
er
ve
d 
B
eh
av
io
r 
(B
eh
av
io
r 
R
at
in
g 
Sc
al
es
),
 C
at
eg
or
ic
al
 O
ut
co
m
es
 a
t 1
2-
m
on
th
 F
ol
lo
w
-u
pa
C
er
eb
ra
l M
al
ar
ia
Se
ve
re
 M
al
ar
ia
l A
ne
m
ia
C
om
m
un
it
y 
C
on
tr
ol
s
V
al
ue
 if
 w
or
se
 
ou
tc
om
e 
in
 I
 a
rm
O
R
 (
95
%
 C
I)
, I
 (
n=
29
) 
vs
. D
 
(n
=2
4)
P
O
R
 (
95
%
 C
I)
, I
 (
n=
21
) 
vs
. D
 
(n
=2
7)
P
O
R
 (
95
%
 C
I)
, I
 (
n=
16
) 
vs
. D
 
(n
=1
5)
P
Fe
ar
fu
l/W
ar
y 
A
ff
ec
t
>
1
2.
55
 (
0.
24
, 2
6.
62
)
0.
43
0.
62
 (
0.
12
, 3
.1
2)
0.
57
0.
80
 (
0.
03
, 1
9.
31
)
0.
89
N
eg
at
iv
e 
A
ff
ec
t
>
1
0.
58
 (
0.
17
, 1
.9
4)
0.
37
0.
92
 (
0.
24
, 3
.5
2)
0.
91
9.
47
 (
0.
83
, 1
08
.4
7)
0.
07
Po
si
tiv
e 
A
ff
ec
t
<
1
0.
94
 (
0.
28
, 3
.1
1)
0.
91
0.
31
 (
0.
09
, 1
.0
9)
0.
07
0.
81
 (
0.
17
, 3
.8
6)
0.
79
O
ve
ra
ll 
H
yp
er
ac
tiv
ity
/O
ve
r-
ac
tiv
ity
>
1
2.
20
 (
0.
71
, 6
.8
4)
0.
17
2.
47
 (
0.
73
, 8
.3
5)
0.
15
1.
89
 (
0.
37
, 9
.7
7)
0.
45
O
ve
ra
ll 
A
da
pt
at
io
n 
to
 C
ha
ng
e/
 
C
oo
pe
ra
tio
n
<
1
1.
09
 (
0.
31
, 3
.8
8)
0.
90
0.
72
 (
0.
20
, 2
.6
0)
0.
62
0.
23
 (
0.
04
, 1
.3
4)
0.
10
a.
B
eh
av
io
r 
R
at
in
g 
Sc
al
e 
ou
tc
om
es
 w
er
e 
co
m
pa
re
d 
by
 lo
gi
st
ic
 r
eg
re
ss
io
n,
 a
dj
us
te
d 
fo
r 
ag
e 
an
d 
se
x
A
bb
re
vi
at
io
ns
: I
, I
m
m
ed
ia
te
 ir
on
; D
, D
el
ay
ed
 ir
on
; P
, P
-v
al
ue
; O
R
, o
dd
s 
ra
tio
; C
I,
 c
on
fi
de
nc
e 
in
te
rv
al
Pediatr Res. Author manuscript; available in PMC 2020 November 13.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
Ssemata et al. Page 19
Ta
b
le
 4
b
.
O
bs
er
ve
d 
B
eh
av
io
r 
(B
eh
av
io
r 
R
at
in
g 
Sc
al
es
),
 C
on
tin
uo
us
 O
ut
co
m
es
 a
t 1
2-
m
on
th
 F
ol
lo
w
-u
pa
C
er
eb
ra
l M
al
ar
ia
Se
ve
re
 M
al
ar
ia
l A
ne
m
ia
C
om
m
un
it
y 
C
on
tr
ol
s
V
al
ue
 if
 w
or
se
 
ou
tc
om
e 
in
 I
 a
rm
M
ea
n 
di
ff
er
en
ce
 (
95
 %
 C
I)
, I
 (
n=
29
) 
vs
. D
 (
n=
24
)
P
M
ea
n 
di
ff
er
en
ce
 (
95
 %
 C
I)
, I
 (
n=
21
) 
vs
. 
D
 (
n=
27
)
P
M
ea
n 
di
ff
er
en
ce
 (
95
 %
 C
I)
, I
 (
n=
16
) 
vs
. D
 (
n=
15
)
P
E
xp
lo
ra
tio
n
<
0
3.
09
 (
−
2.
91
, 9
.1
0)
0.
31
−
0.
66
 (
−
8.
65
, 7
.3
3)
0.
87
−
0.
23
 (
−
7.
97
, 7
.5
1)
0.
95
A
ct
iv
ity
 L
ev
el
<
0
0.
77
 (
−
2.
21
, 3
.7
5)
0.
61
0.
73
 (
−
4.
30
, 5
.7
5)
0.
77
−
1.
09
 (
−
4.
64
, 2
.4
5)
0.
53
a.
L
in
ea
r 
re
gr
es
si
on
 m
od
el
s 
w
er
e 
pe
rf
or
m
ed
 s
ep
ar
at
el
y 
by
 s
tu
dy
 g
ro
up
, a
dj
us
te
d 
fo
r 
ag
e 
an
d 
se
x
A
bb
re
vi
at
io
ns
: I
, I
m
m
ed
ia
te
 ir
on
; D
, D
el
ay
ed
 ir
on
; P
, P
-v
al
ue
; C
I,
 c
on
fi
de
nc
e 
in
te
rv
al
Pediatr Res. Author manuscript; available in PMC 2020 November 13.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
Ssemata et al. Page 20
Ta
b
le
 5
.
So
ci
oe
m
ot
io
na
l a
nd
 E
xe
cu
tiv
e 
Fu
nc
tio
n 
Su
b-
Sc
al
e 
O
ut
co
m
es
 a
t 1
2-
m
on
th
 F
ol
lo
w
-u
pa
C
er
eb
ra
l M
al
ar
ia
Se
ve
re
 M
al
ar
ia
l A
ne
m
ia
C
om
m
un
it
y 
C
on
tr
ol
s
M
ea
n 
di
ff
er
en
ce
 (
95
 %
 C
I)
, I
 (
n=
30
) 
vs
. D
 (
n=
24
)
P
M
ea
n 
di
ff
er
en
ce
 (
95
 %
 C
I)
, I
 (
n=
28
) 
vs
. 
D
 (
n=
32
)
P
M
ea
n 
di
ff
er
en
ce
 (
95
 %
 C
I)
, I
 (
n=
16
) 
vs
. 
D
 (
n=
15
)
P
C
hi
ld
 B
eh
av
io
ra
l C
he
ck
lis
t 
(C
B
C
L
)
A
nx
io
us
/D
ep
re
ss
ed
 z
-s
co
re
s
0.
35
 (
−
0.
12
, 0
.8
2)
0.
14
0.
11
 (
−
0.
50
, 0
.7
2)
0.
72
0.
07
 (
−
0.
65
, 0
.7
8)
0.
85
So
m
at
ic
 C
om
pl
ai
nt
s 
z-
sc
or
es
−
0.
16
 (
−
0.
62
, 0
.2
9)
0.
48
−
0.
05
 (
−
0.
50
, 0
.4
0)
0.
83
0.
13
 (
−
0.
42
, 0
.6
9)
0.
63
W
ith
dr
aw
n 
B
eh
av
io
r 
z-
sc
or
es
−
0.
42
 (
−
0.
94
, 0
.0
9)
0.
11
0.
08
 (
−
0.
59
, 0
.7
6)
0.
81
−
0.
68
 (
−
1.
69
, 0
.3
3)
0.
18
A
tte
nt
io
n 
Pr
ob
le
m
s 
z-
sc
or
es
0.
18
 (
−
0.
31
, 0
.6
7)
0.
47
−
0.
27
 (
−
0.
72
, 0
.1
8)
0.
23
−
0.
38
 (
−
0.
87
, 0
.1
2)
0.
13
A
gg
re
ss
iv
e 
B
eh
av
io
r 
z-
sc
or
es
0.
51
 (
−
0.
05
, 1
.0
8)
0.
07
−
0.
03
 (
−
0.
62
, 0
.5
6)
0.
92
−
0.
34
 (
−
0.
96
, 0
.2
8)
0.
27
B
eh
av
io
ra
l R
at
in
g 
In
ve
nt
or
y 
of
 E
xe
cu
ti
ve
 F
un
ct
io
ni
ng
 (
B
R
IE
F
)
M
et
a 
C
og
ni
tio
n 
In
de
x 
z-
sc
or
e
0.
19
 (
−
0.
56
, 0
.9
4)
0.
61
−
0.
08
 (
−
0.
65
, 0
.4
9)
0.
79
−
0.
42
 (
−
1.
07
, 0
.2
3)
0.
19
Fl
ex
ib
ili
ty
 I
nd
ex
 z
-s
co
re
0.
29
 (
−
0.
27
, 0
.8
5)
0.
30
−
0.
05
 (
−
0.
64
, 0
.5
3)
0.
86
−
0.
11
 (
−
0.
95
, 0
.7
4)
0.
80
In
hi
bi
to
ry
 S
el
f-
C
on
tr
ol
 z
-s
co
re
0.
24
 (
−
0.
43
, 0
.9
2)
0.
48
0.
13
 (
−
0.
48
, 0
.7
3)
0.
67
−
0.
33
 (
−
1.
17
, 0
.5
1)
0.
43
a.
L
in
ea
r 
re
gr
es
si
on
 m
od
el
s 
w
er
e 
pe
rf
or
m
ed
 s
ep
ar
at
el
y 
by
 s
tu
dy
 g
ro
up
 (
C
M
, S
M
A
, C
C
),
 a
dj
us
te
d 
fo
r 
ag
e 
an
d 
se
x
A
bb
re
vi
at
io
ns
: I
, I
m
m
ed
ia
te
 ir
on
; D
, D
el
ay
ed
 ir
on
; P
, P
-v
al
ue
; C
I,
 c
on
fi
de
nc
e 
in
te
rv
al
Pediatr Res. Author manuscript; available in PMC 2020 November 13.
